10-Q: KalVista Pharmaceuticals Reports Q3 2025 Results, Highlights Regulatory Progress for Sebtralstat

KalVista Pharmaceuticals' Q3 2025 report details financial results and provides updates on the regulatory submissions for sebetralstat, its oral on-demand therapy for hereditary angioedema (HAE).

Summary

• KalVista Pharmaceuticals, a pre-commercial stage company, reported its financial results for the quarter ended January 31, 2025.
• The company is focused on developing sebetralstat, an oral treatment for hereditary angioedema (HAE).
• KalVista has submitted regulatory applications for sebetralstat in the US, Europe, Japan, and other territories.
• A New Drug Application (NDA) has been filed with the FDA, with a PDUFA date of June 17, 2025.
• A Marketing Authorization Application (MAA) is under review with the European Medicines Agency (EMA).
• A Japanese New Drug Application has been submitted, and Orphan Drug Designation has been granted.
• The company initiated a pediatric clinical trial (KONFIDENT-KID) using an orally disintegrating tablet (ODT) formulation.
• KalVista entered into a Purchase and Sale Agreement (PSA) with DRI Healthcare Acquisitions LP for up to $179 million, receiving an upfront payment of $100 million.
• The company also completed a common stock offering and private placement in November 2024, raising approximately $56 million in net proceeds.
• Research and development expenses decreased to $12.6 million for the three months ended January 31, 2025, compared to $22.5 million in the same period in the prior fiscal year.
• General and administrative expenses increased to $30.3 million for the three months ended January 31, 2025, compared to $10.6 million in the same period in the prior fiscal year.
• The company had cash, cash equivalents, and marketable securities of $253.2 million as of January 31, 2025.
• KalVista anticipates having sufficient funding to operate for at least the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, it has made significant progress in its regulatory submissions and has secured funding to continue operations. The increase in general and administrative expenses is a concern, but it is likely due to the company preparing for commercialization.

Positives

• Regulatory submissions for sebetralstat are progressing in multiple regions.
• The company secured $100 million in upfront funding through a royalty agreement.
• KalVista raised approximately $56 million through equity offerings.
• The company believes it has sufficient funding for at least the next twelve months.

Negatives

• The company has an accumulated deficit of $600.9 million as of January 31, 2025.
• General and administrative expenses increased significantly, driven by personnel and commercial strategy costs.
• The company has not generated any revenue from product sales and does not expect to generate significant revenue unless and until it obtains regulatory approval for, and commercializes, one of its current or future product candidates.

Risks

• The company is subject to risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations.
• Obtaining regulatory approval for product candidates is not guaranteed.
• The company may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect its business.
• The company may need to raise additional capital in the future.

Future Outlook

KalVista anticipates that it will continue to incur losses for the foreseeable future, and it expects those losses to increase as it continues the development of, and seeks regulatory approvals for, product candidates, and begins to commercialize any approved products. The Company currently anticipates that, based upon its operating plans and existing capital resources, it has sufficient funding to operate for at least the next twelve months.

Management Comments

• We believe people living with HAE are in need of alternatives that better meet their objectives for quality of life and ease of disease control.
• We anticipate that there will be strong interest in a safe and effective, orally delivered on-demand treatment, which would provide patients a new and compelling option with which to treat their disease.

Industry Context

The report highlights the competitive landscape of HAE treatments, noting the need for alternatives to injectable therapies. KalVista aims to address this need with its oral on-demand treatment, sebetralstat, potentially capturing a significant market share if approved.

Comparison to Industry Standards

• The development of an oral on-demand treatment for HAE would differentiate KalVista from companies primarily offering injectable therapies, such as Takeda (Cinryze, Takhzyro) and CSL Behring (Berinert, Haegarda).
• The success of KalVista's sebetralstat hinges on its efficacy and safety profile compared to existing treatments, as well as its convenience of oral administration.
• Comparable companies in the rare disease space often rely on strategic partnerships and licensing agreements to expand their market reach, a strategy KalVista is also pursuing.

Stakeholder Impact

• Shareholders: The report provides information on the company's financial performance and progress in developing sebetralstat.
• Employees: The company is expanding its infrastructure to support the commercialization of sebetralstat, which may create new job opportunities.
• Patients: If approved, sebetralstat would provide a new oral on-demand treatment option for HAE patients.
• Creditors: The company has sufficient funding to operate for at least the next twelve months, which reduces the risk of default.

Next Steps

• Continue to advance regulatory submissions for sebetralstat in the US, Europe, and Japan.
• Advance the KONFIDENT-KID pediatric clinical trial.
• Continue development of the oral Factor XIIa inhibitor program.
• Prepare for the potential commercial launch of sebetralstat.

Key Dates